The generics industry does not appear satisfied with an FDA proposal to treat all applications equally under a new generic drug user fee program, preferring instead to create another, separate user fee that would clear the ANDA application backlog faster.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
